Herpes zoster after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: a prospective study활동적으로 치료받고 있는 암 환자에서 SARS-CoV-2 mRNA-BNT162b2 백신의 세 번째 접종 후 대상포진: 전향적 연구Article Published on 2024-01-202024-08-16 Journal: Clin Exp Med [Category] 대상포진, [키워드] active treatment COVID-19 vaccine herpes zoster SARS-CoV-2 solid tumors T cell third dose
Herpes zoster after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: a prospective studyResearch Published on 2024-01-202024-09-05 Journal: Clinical and experimental medicine [Category] update2024, [키워드] active treatment COVID-19 vaccine herpes zoster SARS-CoV-2 solid tumors T cell third dose [DOI] 10.1007/s10238-023-01263-2 PMC 바로가기 [Article Type] Research
SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignanciesArticle Published on 2022-10-012022-11-15 Journal: American journal of hematology [Category] COVID19(2023년), SARS, 진단, [키워드] active treatment B-cell malignancies B-cell malignancy BNT162b2 BNT162b2 vaccine booster booster dose Comparisons Control COVID19 disease dose elicited ENhance enrolled evaluated healthy controls high-risk population Humoral response immune response leukemia median NAb nAb response NAb titer NAbs NHL Patient patient group patients Prognostic factor proportion Protective response SARS-CoV-2 SARS-CoV-2 neutralizing antibody SARS-CoV-2 vaccination significantly significantly lower Treatment vaccination [DOI] 10.1002/ajh.26669 PMC 바로가기
Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases혈액 질환 환자에서 코로나19 백신 접종 후 항체 음성 반응과 관련된 요인 정의Article Published on 2022-08-012022-09-12 Journal: Annals of Hematology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] active treatment addition age Analysis antibody Antibody Response AstraZeneca BNT162b2 BTK inhibitor CML Combination Concentration correlated COVID-19 COVID-19 vaccination Definition demonstrated disease Efficacy Factor had no hematological Hematological diseases/disorders high mortality knowledge leukemia lymphoid median age Moderna mRNA-1273 naïve negative antibody response neoplasm Neoplasms not correlated other disease other diseases Patient patient cohort positive positive response reduced response to vaccination ruxolitinib SARS-CoV-2 Seroconversion significantly single-center study Spike protein Surveillance the SARS-CoV-2 therapy treated Treatment vaccination was performed were measured women [DOI] 10.1007/s00277-022-04866-z PMC 바로가기 [Article Type] Article
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccinesmRNA 백신 추가 접종 후 활성 요법을 받는 암 환자의 SARS-CoV-2 감염Article Published on 2022-08-012022-09-11 Journal: European journal of cancer (Oxford, England : 1990 [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] active treatment anti-Spike IgG booster booster dose Booster vaccine cancer patient Cancer patients center Cohort COVID-19 Delta dose Follow-up geometric mean geometric mean titer geometric mean titers Health care Health care worker healthy subject healthy subjects indicate investigated Italy lowest malignancies median value microneutralization Microneutralization assay mRNA vaccine mRNA vaccines Nasopharyngeal swab Neutralizing antibodies neutralizing antibody Occurrence occurrence of COVID-19 omicron Omicron variants outbreak Patient positive potential risk proportion protective role required SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants serological Siena solid malignancies solid malignancy solid tumor solid tumors tested the median the SARS-CoV-2 therapy Treatment tumors Type university Vaccine variants [DOI] 10.1016/j.ejca.2022.05.018 PMC 바로가기 [Article Type] Article
Correlation Analysis of Positive Therapy Based on High Content Image Analysis Technology on Posttraumatic Nerve Growth in Patients with COVID-19 in the Context of Intelligent Medical TreatmentRandomized Controlled Trial Published on 2022-07-192022-10-05 Journal: Contrast media & molecular imaging [Category] COVID19(2023년), SARS, 임상, [키워드] active treatment Anxiety content Context control group Coronavirus pneumonia correlation crown Depression Diseases disorder early recovery Effect eliminating emotional evaluated growth hospital Image incidence incidence rate introduced Isolation maintain Mental disorder negative emotions nerve novel Novel coronavirus observation Patient patients Pneumonia positive Posttraumatic Stress promote Psychological PTSD randomly divided reduced rehabilitation selected significantly technology therapy treated Treatment with COVID-19 Wuhan [DOI] 10.1155/2022/9165764 PMC 바로가기 [Article Type] Randomized Controlled Trial
Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination고형암 환자는 SARS-CoV-2 백신 접종 후 적절한 면역원성과 낮은 중증 부작용 발생률 달성Article Published on 2022-07-012022-09-11 Journal: Future Oncology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료제, [키워드] A significant reduction active treatment Adverse adverse events anti-SARS-CoV-2 S1 IgG antibody antibody level antibody levels anticancer anticancer treatment cancer patient Cancer patients Complete Course COVID-19 disease event healthy controls Immune checkpoint inhibitor Immune checkpoint inhibitors immunogenicity Mild mRNA mRNA-based mRNA-based vaccination mRNA-based vaccine participant Patient patients Prevent receiving Result SARS-CoV-2 vaccination SARS-CoV-2 vaccine second dose Seroconversion seroconversion rate serum severe adverse event severe COVID-19 disease Solid solid cancer therapy Treatment vaccination [DOI] 10.2217/fon-2022-0148 PMC 바로가기 [Article Type] Article
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies항암치료를 받는 환자의 코로나19 백신접종에 대한 항체 및 T세포 반응Article Published on 2022-06-012022-09-11 Journal: Journal for immunotherapy of cancer [Category] COVID19(2023년), MERS, SARS, 바이오마커, 변종, 진단, 치료기술, 치료제, [키워드] active treatment adrenal crisis Adrenal insufficiency Affect Anti-CD20 antibodies Anti-CD20 antibody Anti-viral antibodies antibody antibody formation Antibody titer Antibody titers Anticancer therapy B cells B-cell B.1.617.2 blockade Cancer CD4 CD8 Cell cellular Chemoimmunotherapy Chemotherapy Corticosteroids COVID-19 COVID-19 infection COVID-19 infections COVID-19 vaccination COVID-19 vaccinations COVID-19 vaccine trials cross-reactive cytokine detectable develop dose doses effector cells Endocrine expressed follicular generate healthy donor healthy donors helper cells Humoral response hypoadrenalism Hypothesis IgG antibody titer immune Immunocompromised immunogenic immunogenicity immunogenicity, vaccine Immunotherapy intracellular cytokine staining Lymphocytes mRNA vaccine Multiple myeloma Myeloma n=36 no differences oncology patients Participants Patient Patients with cancer PD-1 peptide peptides Phase 3 profile Prophylactic RBD reactivity receiving Receptor binding domain Safe seronegative seronegative patient Side effect solid tumors spike Spike protein steroid Steroids Stress symptomatic T cell T cell response T cell responses T cells T follicular helper cells T-lymphocytes targeted therapy the SARS-CoV-2 therapy Treatment treatment groups tumors Two patient two patients vaccination Vaccinations Vaccine variant spike was measured were assessed were excluded wild-type WT spike [DOI] 10.1136/jitc-2022-004766 PMC 바로가기 [Article Type] Article
Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis혈액암 환자에서 코로나19 백신의 면역원성: 체계적 고찰 및 메타분석Meta-Analysis Published on 2022-04-122022-09-12 Journal: Blood advances [Category] COVID19(2023년), SARS, 진단, [키워드] active treatment adverse event Analysis approach cellular response Cellular responses clinical study Cochrane Central conducted Confidence intervals COVID-19 infection COVID-19 vaccination COVID-19 vaccine disease dose doses expressed first dose healthy control hematologic highest immune response immunogenicity leukemia lowest malignancies malignancy Meta-analysis monoclonal antibody morbidity and mortality Neutralizing antibodies Neutralizing antibody response New Odds ratio outcome Patient patient group positive random effect Rate reduce required respond poorly second dose Secondary outcomes single-arm study stratified systematic review therapy Treatment [DOI] 10.1182/bloodadvances.2021006333 PMC 바로가기 [Article Type] Meta-Analysis
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study활성 치료 중인 고형 종양 환자에서 BNT162b2 항-SARS-CoV-2 백신 3차 접종 후 면역원성과 안전성: 전향적 코호트 연구Article Published on 2022-04-012022-09-11 Journal: ESMO open [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] active treatment acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration anti-SARS-CoV-2 antibody baseline BNT162b2 BNT162b2 anti-SARS-CoV-2 vaccine booster booster dose Cancer cancer patient Cancer patients cell-mediated immune cell-mediated immune response Concentration consecutive patient coronavirus coronavirus disease Coronavirus disease 2019 Course COVID-19 COVID-19 infection Delta dose effective Efficacy enrolled evaluated Gamma humoral IgG IgG antibody immunogenicity Immunoglobulin Immunoglobulin G interferon interferon gamma interferon-γ interquartile range IQR median Messenger RNA naïve naïve subject naïve subjects neutralization Neutralizing neutralizing antibody of BNT162b2 omicron Patient patients Preliminary data primary endpoint prospective cohort study quantified reached recruited Release respiratory SARS-CoV-2 SARS-CoV-2 vaccine serum severe acute respiratory syndrome Coronavirus significantly higher solid cancer solid tumor subject subjects the median the SARS-CoV-2 third dose Treatment Trigger Vaccine variant variants variants of concern VOCs were used whole blood sample wild-type strain [DOI] 10.1016/j.esmoop.2022.100458 PMC 바로가기 [Article Type] Article